If your child’s current juvenile idiopathic arthritis treatment isn’t relieving their joint pain, stiffness and swelling, HUMIRA may help
HUMIRA helps reduce pain, stiffness and swelling in children
HUMIRA is a treatment that may help to reduce the signs and symptoms of moderate to severe JIA, even in children who have not been helped enough by other non-biologic medications. HUMIRA is usually used with methotrexate, or alone, when methotrexate is no longer working well enough, or no longer appropriate. HUMIRA may be an effective option for some children.
HUMIRA is a biologic disease-modifying anti-rheumatic drug, also called a biologic DMARD, or simply “biologic”. HUMIRA works differently to conventional DMARDs because it works by identifying and blocking a specific source of inflammation that contributes to polyarticular juvenile idiopathic arthritis symptoms.
HUMIRA is only available on prescription for children with polyarticular JIA two years of age and older. Talk to your child’s rheumatologist or specialist to see if HUMIRA is right for them.
The government medicine funding agency, PHARMAC, fully subsidises HUMIRA for your child’s polyarticular JIA if they have not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your child’s specialist will discuss whether HUMIRA is right for your child, and whether your child may qualify for PHARMAC funded treatment. Usual doctor’s consultation fees, and pharmacy prescription charges remain payable by you.
A clinical study showed you can expect fewer disease flares when treated with HUMIRA (both alone and in combination with methotrexate), compared to no HUMIRA treatment. It was also shown you may expect around 7 out of 10 children on HUMIRA alone, and 9 out of 10 children on HUMIRA and methotrexate, to experience a reduction in symptoms after four months of treatment.2,§
What is HUMIRA and how does it work?
HUMIRA (adalimumab) belongs to a group of medicines called biologics. Biologics are injectable protein-based therapies (often antibodies). HUMIRA binds to a specific protein, tumour necrosis factor (TNF), which is present at increased levels in inflammatory conditions such as polyarticular juvenile idiopathic arthritis. Inflammation associated with polyarticular juvenile idiopathic arthritis can be caused by an over-production of the protein tumour necrosis factor (TNF). Polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and psoriasis are some examples of autoimmune diseases. The cause of autoimmune diseases is currently not well understood but it has been found that increased levels of a protein called TNF plays a key role in the excessive inflammation that is a feature of these diseases. TNF triggers inflammation as part of the body’s normal immune system response, however excess TNF can attack normal, healthy body tissue and cause inflammation. HUMIRA binds to TNF and helps reduce the pain and inflammation associated with autoimmune diseases.
Will HUMIRA cure my/my child's disease?
Unfortunately, currently there are no treatments available that can cure polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, or psoriasis. HUMIRA will not cure your child’s condition but can help manage their symptoms.
How well does HUMIRA work?
HUMIRA, alone or in combination with methotrexate, is an effective treatment option for many children with polyarticular juvenile rheumatoid arthritis. Based on clinical study results, responses were sustained through 2 years of continued treatment.3,§